NCT03620474View on ClinicalTrials.gov

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

July 13, 2021

Study Completion Date

February 28, 2022

Conditions
Hepatitis CHepatitis BLiver Cirrhoses
Interventions
DRUG

PRI-724

twice a week for 4 hours continuous intravenous administration of PRI-724

Trial Locations (3)

272-8516

Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa

113-8677

Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku

812-8582

Kyushu University Hospital, Fukuoka

Sponsors
All Listed Sponsors
collaborator

Prism Pharma Co., Ltd.

INDUSTRY

collaborator

Kyushu University

OTHER

collaborator

National Center for Global Health and Medicine, Japan

OTHER_GOV

collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

collaborator

Ohara Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kiminori Kimura, MD

OTHER

NCT03620474 - Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis | Biotech Hunter | Biotech Hunter